Key Takeaways

A retrospective cohort study suggested that users of GLP-1 receptor agonists had a 7% higher incidence of new-onset diabetic retinopathy.

In patients with existing diabetic retinopathy, use of GLP-1 drugs was not associated with an increased risk of progression to proliferative retinopathy or diabetic macular edema.

Regular ophthalmic screening should be recommended for all patients taking GLP-1 agonists for diabetes.

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor agonists for diabetes, despite a lower risk of vision-threatening complications, a large retrospective study suggested.

A propensity-matched comparison showed a 7% higher incidence of new DR among users of GLP-1 agonists. The risk of isch

See Full Page